Monday, September 21, 2009

Jennerex Closes $5.5M Series C

San Francisco-based Jennerex, a developer of oncolytic virus therapeutics, said late last week that it has closed its second tranche of Series C funding. The firm said the round close dout at $5,611,475, above the firm's target of $5M. The firm had announced the fundraising effort in August. Source of the funds was not disclosed. The company's compounds are being applied to treating liver cancer, where it says it hopes to complete a Phase Ii trial in the next 12 months, with plans for Phase I trials in solid cancers and a Phase II trail for treating colorectal cancer.